ABOUT GLENMARK PHARMACEUTICALS
Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in bran-ded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also market APIs to regulated and semi-regulatedcountries. Glenmark employs nearly 6000 people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres.
Glenmark in South Africa
The South African office was was launched in December 2005 when Glenmark acquired Bouwer Bartlett, a local pharmaceutical company specializing in dermatological products. One of the company’s key strategies was to buy into existing pharmaceutical companies and product ranges in the South African pharm-aceutical industry, which was quickly gaining momentum at this time.
In June 2006, Glenmark acquired a range of products called PD Pharmaceuti-cals, which are now also offered under Glenmark’s diverse range of products. In July 2009, the company bought Covarex in order to broaden their range of derm-atological products on offer.
The company has been based in Midrand since its inception in 2005. What started as a smaller organization with seven employees has now grown to a busy, innovative company with 25 people. From April 2012, a total of 35 people will be working at Glenmark Pharmaceuticals South Africa.
Glenmark South Africa also handles the local distribution of products from French company Boiron Laboratories as well as the distribution of Spanish company
Awards and recognition
Glenmark was chosen as the “Best Pharma Company in the World – SME” and “Best Company across emerging markets” for 2008 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. Forbes, another leading international publication, recognized Glenmark as the “Best under a Billion Dollar companies in Asia” for 2008.
The company has also recieved recognitions for being the “Indian Innovator Pharmaceutical Company of the Year” and a “Silver Patent Award” in “NCE/Drug Discovery Patent Category” by Frost & Sullivan and Pharmexcil respectively.
In 2011, SCRIP (a leading global pharmaceutical and biotech news publication) honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who’s Who of the world pharmaceutical industry, on November 3 ; Glenmark was presented with ‘Best Company in Emerging Markets’ & ‘Best Overall Pipeline’ recognitions for the year 2011.
Specialty business : Formulations Business
Glenmark’s formulations business is currently organized around four regions- India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS.
The formulations business focuses on therapeutic areas viz. dermatology,anti-infectives,respiratory,cardiac,diabetes,gynecology,CNS,and oncology. India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/branded formulations for global markets.